Arsanis Inc.

Industry

  • Biotechnology
    • Large Molecule
      • Antibodies
  • Pharmaceuticals

Other Names/Subsidiaries

  • Arsanis Biosciences GmbH
See more in Biomedtracker

Latest on Arsanis Inc.

Scrip

Finance Watch: Turning Point Launches IPO, Stock Rises 60% On First Day

 
• By Mandy Jackson

Turning Point Therapeutics Inc. , which specializes in tyrosine kinase inhibitors (TKIs) for cancer, had one of the best-performing initial public offerings by a biopharmaceutical company this year wh

Scrip

Deal Watch: Boehringer Teams Up In CNS Disorders Again, This Time With Domain

 
• By Joseph Haas, Alex Shimmings, John Davis, Jessica Merrill, Jo Shorthouse, and Eleanor Malone

Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Strategic Transactions . Boehringer Ingelheim Taps In

Scrip

IPOs In Review: Biopharma Offerings Bounced Back In 2017 As Returns Rose

 
• By Mandy Jackson

Biopharmaceutical companies launched 42 initial public offerings in the US in 2017 versus 30 in 2016 as stock values rose. But biotechnology in general endured a rough fourth quarter, raising the ques

In Vivo

Deals Shaping The Medical Industry, December 2017

 
• By Beth Allan, Deanna Kamienski, and Maureen Riordan

IN VITRO DIAGNOSTICS Alliances Clearbridge BioMedics Pte. Ltd. Danaher Corp. Leica Biosystems Ltd. Leica Biosystems Ltd. and Clearbridge BioMedics Pte. Ltd. will co-promote each other’s automa